title: [Tuberculosis].
abstract: The incidence of tuberculosis in Japan is the highest among developed countries, with approximately 42,000 new cases reported in 1997, marking the first increase in 38 years. The growing incidence among the elderly and group infections among young adults may be responsible for this increase. Infection with tubercle bacilli(TB) occurs via airborne transmission, which involves dissemination of either airborne droplet nuclei on evaporated droplets that may remain suspended in the air for long periods of time. Microorganisms carried in this manner can be dispersed widely by air currents, therefore, special air handling and ventilation are required to prevent airborne transmission. Patients with infectious TB must be placed in a single room with negative pressure and a ventilation rate of 6 or more air changes per hour. Health care workers must wear an N95 mask when entering the room, and if an incident involving possible TB infection occurs in the hospital, the concerned people should be examined for Tuberculin reaction. Two to 12 weeks after the TB infection has occurred, the tuberculin reaction converts to positive. However, most Japanese people have been vaccinated with BCG, so assessment of the results is difficult. A comparison of the diameter of erythema before and after the potential infection may be the most confirmatory. If latent TB infection is suspected, preventive therapy with isoniazid must be considered. Special biohazard systems in the clinical laboratory and autopsy room have also been proposed to prevent TB dispersal. DOTS(Directly Observed Treatment, Short-course) is useful to prevent the emergence of multi-drug-resistant TB. In some areas of Japan that have low levels of compliance with TB therapy, trials of DOTS have been started.
authors.affiliation: Department of Clinical Laboratory, Nagoya University Hospital, Nagoya, Aichi-pref. 466-8560.
authors.forename: Y
authors.initials: Y
authors.lastname: Iinuma
mesh_terms: D000995:Antitubercular Agents / Q000008:administration & dosage; D001500:BCG Vaccine; D003428:Cross Infection / Q000517:prevention & control; D006801:Humans; D017758:Infectious Disease Transmission, Patient-to-Professional / Q000517:prevention & control; D007538:Isoniazid / Q000008:administration & dosage; D007564:Japan / Q000453:epidemiology; D015995:Prevalence; D014374:Tuberculin Test; D014376:Tuberculosis / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D000995:Antitubercular Agents; D001500:BCG Vaccine; D007538:Isoniazid